Gender-specific 30-day outcomes after carotid endarterectomy and carotid artery stenting in the Society for Vascular Surgery Vascular Registry  by Jim, Jeffrey et al.
From the Society for Vascular SurgeryFrom
M
bu
va
V
A
sio
an
*Me
The
ex
Auth
Pres
Su
Rep
N
02
The
to
m
0741
Cop
http
742Gender-speciﬁc 30-day outcomes after carotid
endarterectomy and carotid artery stenting in the
Society for Vascular Surgery Vascular Registry
Jeffrey Jim, MD,a Ellen D. Dillavou, MD,b Gilbert R. Upchurch, Jr, MD,c Nicholas H. Osborne, MD,d
Christopher T. Kenwood, MS,e Flora S. Siami, MPH,e, Rodney A. White, MD,f and
Joseph J. Ricotta II, MD,g for the SVS Outcomes Committee*, St. Louis, Mo; Pittsburgh, Pa; Charlottesville,
Va; Ann Arbor, Mich; Watertown, Mass; Los Angeles, Calif; and Atlanta, Ga
Objective: Although theoptimal treatmentof carotid stenosis remainsunclear, availabledata suggest thatwomenhavehigher
riskof adverse events after carotid revascularization.Weuseddata fromtheSociety forVascular SurgeryVascularRegistry to
determine the effect of gender on outcomes after carotid endarterectomy (CEA) and carotid artery stenting (CAS).
Methods: There were 9865 patients (40.6% women) who underwent CEA (n[ 6492) and CAS (n[ 3373). The primary
end point was a composite of death, stroke, and myocardial infarction at 30 days.
Results: There was no difference in age and ethnicity between genders, but men were more likely to be symptomatic
(41.6% vs 38.6%; P < .003). There was a higher prevalence of hypertension and chronic obstructive pulmonary disease in
women, whereas men had a higher prevalence of coronary artery disease, history of myocardial infarction, and smoking
history. For disease etiology in CAS, restenosis was more common in women (28.7% vs 19.7%; P < .0001), and radiation
was higher in men (6.2% vs 2.6%; P < .0001). Comparing by gender, there were no statistically signiﬁcant differences in
the primary end point for CEA (women, 4.07%; men, 4.06%) or CAS (women, 6.69%; men, 6.80%). There remains no
difference after stratiﬁcation by symptomatology and multivariate risk adjustment.
Conclusions: In this large, real-world analysis, women and men demonstrated similar results after CEA or CAS. These data
suggest that, contrary to previous reports, women do not have a higher risk of adverse events after carotid revascular-
ization. (J Vasc Surg 2014;59:742-8.)3-6Cerebrovascular disease is a leading cause of death and
the leading cause of serious long-term disability in the
United States.1,2 Carotid revascularization is an essential
treatment option for select patients with signiﬁcant internal
carotid artery stenosis. Carotid endarterectomy (CEA)
remains considered by many to be the gold standard proce-
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://dx.doi.org/10.1016/j.jvs.2013.09.036the past 2 decades. Since its introduction, carotid angio-
plasty and stenting (CAS) has been touted as an alternative
to CEA.7,8 Although the clinical efﬁcacy and effectiveness
of CAS compared with CEA remain debated, there is clear
utility in patients with select high-risk criteria.9-11
Gender plays an important role in cardiovascular
disease. Epidemiologic studies have demonstrated that
men have a higher incidence and prevalence rate of stroke
than women.12 The strokes that do occur in women tend
to be more severe, however. In terms of revascularization,
the available literature suggests that women have higher
risk of perioperative adverse events.5,6 This thus puts into
question how much women actually beneﬁt from carotid
revascularization compared with men.
The Society for Vascular Surgery (SVS) Vascular
Registry (VR) on carotid procedures was developed to
collect long-term outcomes on patients treated with CEA
and CAS.13 As the ﬁrst societal registry to enroll CEA
and CAS patients, the VR is one of the largest published
databases of carotid revascularization procedures in the
United States. The purpose of this study was to use the
SVS-VR to determine the effect of gender on outcomes
after CEA and CAS.
METHODS
VR data are reported by providers through Web-based
electronic data capture. The measurement schedule
includes baseline (preoperative) information, such as
patient demographics, medical history, carotid symptom
Table I. Baseline demographics, disease etiology, and
medical history
Variablea
Female
(n ¼ 4008)
Male
(n ¼ 5857) Pb
Age, years 71.1 (18-95) 70.9 (35-98) .2874
WhitedCaucasian 92.4 (3705) 92.8 (5434) .5302
Hispanic 3.5 (139) 3.4 (200) .9104
Etiology
Atherosclerosis 88.9 (3563) 89.9 (5268) <.0001
Radiation 0.9 (37) 2.3 (132)
Restenosis 10.2 (408) 7.8 (457)
Carotid symptomatology,
% symptomatic
38.6 (1547) 41.6 (2439) .0026
Stroke 21.6 (864) 23.2 (1358) .0589
Transient ischemic attack 20.4 (817) 20.7 (1210) .7608
Transient monocular
blindness
5.5 (219) 6.5 (379) .0434
Any high-risk factorc 54.7 (2192) 55.4 (3245) .4843
aContinuous variables are presented as mean (range) and categoric variables
as percentage (number).
bP value for age was found using the t-test. All others were found using the
c2 test.
cHigh-risk factors, as deﬁned by Center for Medicare and Medicaid Services,
include age >80 years, New York Heart Association Congestive Heart
Failure Class III/IV, ejection fraction <30%, unstable angina, myocardial
infarction (MI) #30 days, restenosis, radical neck dissection, contralateral
occlusion, prior radiation to neck, contralateral laryngeal nerve injury, and
high anatomic lesion.
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values; procedural information, including procedural and
predischarge complications; and follow-up information
such as postprocedure mortality, stroke, myocardial infarc-
tion (MI), and other morbidity. All data entered into the
VR are fully compliant with the Health Insurance Porta-
bility and Accountability Act regulations and are auditable.
All data reports and analyses performed included only de-
identiﬁed and aggregated data. Additional details regarding
the SVS-VR have been previously discussed.13 New
England Research Institutes Inc (NERI, Watertown,
Mass) maintains the online database. Funding for the
administration and database management of the VR has
been provided by the SVS (Chicago, Ill).
Outcomes. The primary outcome measure is
a composite of the incidence of death, stroke, or MI.
Stroke is deﬁned as any nonconvulsive, focal neurologic
deﬁcit of abrupt onset persisting >24 hours. The ischemic
event must correspond to a vascular territory. An MI is
classiﬁed as:
d A Q wave MI in which one of the following criteria is
required: (1) chest pain or other acute symptoms
consistent with myocardial ischemia and new patho-
logic Q waves in two or more contiguous electrocar-
diogram (ECG) leads; or (2) new pathologic Q
waves in two or more contiguous ECG leads and eleva-
tion of cardiac enzymes; or
d A non-Q wave MI, which is deﬁned as creatinine
kinase ratio >2 and creatinine kinase-myocardial
band >1 in the absence of new, pathologic Q waves.
Analysis of the 30-day outcomes was based on only
those patients who had at least a 30-day follow-up visit
(>16 days) or who experienced an end point (death,
stroke, or MI) #30 days of treatment.
Statistical methods. Tests of statistical signiﬁcance
were conducted with c2 or Fisher exact tests for categoric
variables and t-tests for continuous variables. Descriptive
statistics are listed as mean6 standard deviation for contin-
uous variables and percentage (frequency) for categoric
variables. Subset analyses were performed using the two-
tailed t-test for continuous variables and the Fisher exact
test for discrete and categoric data. Unadjusted and
adjusted odds ratios (ORs) found through multivariate
logistic regression were used to compare the primary
outcomes across subgroups and are presented with 95%
conﬁdence intervals (CIs). ORs were adjusted for signiﬁ-
cant baseline factors that were retained after applying the
backward elimination method. Differences were considered
signiﬁcant if P was < .05. All statistical analyses were per-
formed by NERI using SAS statistical software (SAS
Institute, Cary, NC).
RESULTS
For the purpose of this study, the analysis was limited
to patients treated for carotid disease caused by atheroscle-
rosis, radiation, and restenosis. This led to an exclusion of454 patients treated for alternative etiologies (eg, dissec-
tion, ﬁbromuscular dysplasia, and trauma). There were
9865 patients who had 30-day follow-up data, with
40.6% women (n ¼ 4008) and 59.4% men (n ¼ 5857).
For CEA (65.8%; n ¼ 6492), there were 41.3% women
(n ¼ 2678) and 58.7% men (n ¼ 3814). For CAS
(34.2%; n ¼ 3373), there were 39.4% women (n ¼
1330) and (60.6%) men (n ¼ 2043). The characteristics
of the two gender groups can be found in Table I. Men
and women had a similar age and ethnicity proﬁle. Women
were more likely to be treated for restenosis (10.2% vs
7.8%) and less often for radiation-induced disease (0.9%
vs 2.3%). Men were more likely to be treated for symptom-
atic disease (41.6% vs 38.6%). There was an equal preva-
lence (55%) of patients with at least one high-risk factor
as deﬁned by the Center for Medicare and Medicaid
Services.
The patient characteristics after separation by proce-
dure and gender can be found in Table II. For both proce-
dures, the age and ethnicity distribution were similar.
There was a low prevalence (<2%) of CEA patients treated
for radiation or restenosis. Men were more likely to be
symptomatic (39.2% vs 35.8%; P < .007), driven by
a higher (22.2% vs 19.2%; P ¼ .004) previous history of
stroke. For CAS patients, women had a higher prevalence
of restenosis (28.7% vs 19.7%), and men were more likely
to be treated for radiation-induced disease (6.2% vs
2.6%). The distribution by medical history within the two
procedures was similar. Men tended to have a higher prev-
alence of coronary artery disease and history of MI and
Table II. Baseline demographics, disease etiology, medical history, and carotid evaluationdstratiﬁed by procedure
Variablea
CEA patients CAS patients
Female (n ¼ 2678) Male (n ¼ 3814) Pb Female (n ¼ 1330) Male (n ¼ 2043) Pb
Age, years 71.0 (37-95) 70.7 (35-98) .2295 71.2 (18-94) 71.2 (35-96) .8184
WhitedCaucasian 92.5 (2477) 93.0 (3546) .4655 92.3 (1228) 92.4 (1888) .9471
Hispanic 3.0 (81) 2.7 (102) .4032 4.4 (58) 4.8 (98) .6149
Etiology
Atherosclerosis 99.0 (2650) 98.4 (3754) .1787 68.6 (913) 74.1 (1514) <.0001
Radiation 0.1 (2) 0.2 (6) 2.6 (35) 6.2 (126)
Restenosis 1.0 (26) 1.4 (54) 28.7 (382) 19.7 (403)
Carotid symptomatology, % symptomatic 35.8 (960) 39.2 (1494) .0069 44.1 (587) 46.3 (945) .2292
Stroke 19.2 (514) 22.2 (845) .0040 26.3 (350) 25.1 (513) .4431
Transient ischemic attack 19.1 (511) 19.1 (729) >.9999 23.0 (306) 23.5 (481) .7390
TMB 4.9 (131) 5.7 (217) .1623 6.6 (88) 7.9 (162) .1585
Medical history
Coronary artery disease 40.4 (1082) 53.8 (2053) <.0001 51.8 (689) 63.2 (1291) <.0001
MI 12.8 (344) 18.9 (719) <.0001 20.1 (267) 23.6 (482) .0176
Valvular heart disease 8.8 (235) 7.2 (276) .0246 6.3 (84) 6.0 (122) .7131
Cardiac arrhythmia 11.2 (301) 14.2 (540) .0006 14.4 (191) 15.0 (307) .6196
Congestive heart failure 8.3 (221) 7.6 (288) .3026 15.0 (199) 14.2 (290) .5484
Hypertension 85.4 (2287) 83.4 (3182) .0320 86.8 (1155) 81.1 (1657) <.0001
Diabetes 31.1 (833) 31.8 (1212) .5689 36.2 (481) 34.2 (699) .2523
COPD 18.9 (505) 16.9 (645) .0440 22.3 (296) 19.3 (394) .0401
Chronic renal failure 2.9 (79) 3.7 (140) .1244 3.4 (45) 4.1 (84) .3126
Peripheral vascular disease 44.8 (1199) 42.2 (1611) .0444 37.1 (494) 37.2 (760) >.9999
GI ulcer/bleeding 3.6 (96) 2.7 (102) .0399 5.4 (72) 4.4 (89) .1610
Current or past smoker 56.8 (1521) 63.4 (2419) <.0001 54.0 (718) 65.8 (1344) <.0001
Cancer 12.3 (330) 13.5 (514) .1774 14.2 (189) 23.0 (469) <.0001
Coagulopathy 1.2 (32) 1.5 (58) .2829 1.4 (19) 0.7 (14) .0472
ASA grade <3 92.2 (2468) 90.2 (3440) .0063 90.7 (1206) 92.8 (1896) .0276
NYHA scale <2 95.2 (2550) 95.5 (3644) .5474 88.9 (1182) 88.5 (1809) .7814
Aspirin or clopidogrel 87.1 (2333) 88.1 (3359) .2502 95.6 (1272) 96.3 (1968) .3205
Any high-risk factorc 36.7 (984) 36.5 (1394) .8729 90.8 (1208) 90.6 (1851) .8260
Carotid evaluation
Baseline ultrasound imaging >80% 68.8 (1717) 70.5 (2500) .1548 77.6 (923) 77.5 (1362) >.9999
Contralateral stenosis >70% 18.1 (482) 19.0 (722) .3636 26.1 (342) 24.1 (489) .2190
Stent information
Use of embolic protection 96.7 (1286) 97.7 (1997) .0797
No. of stents, >1 8.3 (110) 6.5 (133) .0565
ASA, American Society of Anesthesiologists; CAS, carotid artery stenting; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; GI,
gastrointestinal; MI, myocardial infarction; NYHA, New York Heart Association; TMB, transient monocular blindness.
aContinuous variables are presented as mean (range) and categoric variables as percentage (number).
bP value for age was found using the t-test. P value for etiology was found using the c2 test. All others were found using the Fisher exact test.
cHigh-risk factors, as deﬁned by Center for Medicare and Medicaid Services, include age >80 years, NYHA Congestive Heart Failure Class III/IV, ejection
fraction <30%, unstable angina, MI #30 days, restenosis, radical neck dissection, contralateral occlusion, prior radiation to neck, contralateral laryngeal nerve
injury, and high anatomic lesion.
Table III. Thirty-day outcomes for patients undergoing
carotid endarterectomy (CEA)a
30-day events
CEA patients, % (No.)
Female (n ¼ 2678) Male (n ¼ 3814) Pb
Mortality 0.86 (23) 0.87 (33) >.9999
Stroke 2.58 (69) 2.49 (95) .8724
MI 1.16 (31) 1.26 (48) .7320
Death, stroke,
or MI
4.07 (109) 4.06 (155) >.9999
MI, Myocardial infarction.
aEvents were deﬁned as any event occurring intraoperatively, before
discharge, or between discharge and 30 days. Rates are per-patient.
bP values were based on the Fisher exact test.
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744 Jim et al March 2014tobacco use, whereas women had a higher prevalence of
hypertension and chronic obstructive pulmonary disease.
There was no difference in the use of antiplatelet therapy
or the presence of Center for Medicare and Medicaid
Services high-risk factors. The differences between the
percentages of men and women with baseline ultrasound
stenosis >80% or contralateral stenosis >70% were not
statistically signiﬁcant.
CEA patients. In patients undergoing CEA
(Tables III and IV), there was no statistically signiﬁcant
difference in the 30-day outcomes. The primary end point
was nearly identical (4.07% female and 4.06% male), as
were the individual end points of mortality, stroke, or MI.
Asymptomatic patients undergoing CEA had the lowest
event rates, with the composite death/stroke/MI rate
Table IV. Thirty-day outcomes for symptomatic and asymptomatic patients undergoing carotid endarterectomy (CEA)a
30-day events
Asymptomatic CEA, % (No.) Symptomatic CEA, % (No.)
Female (n ¼ 1718) Male (n ¼ 2320) Pb Female (n ¼ 960) Male (n ¼ 1494) Pb
Mortality 0.64 (11) 0.82 (19) .5813 1.25 (12) 0.94 (14) .5453
Stroke 1.51 (26) 1.68 (39) .7062 4.48 (43) 3.75 (56) .4007
MI 1.28 (22) 1.21 (28) .8859 0.94 (9) 1.34 (20) .4462
Death, stroke, or MI 3.03 (52) 3.19 (74) .7845 5.94 (57) 5.42 (81) .5912
MI, Myocardial infarction.
aEvents were deﬁned as any event occurring intraoperatively, before discharge, or between discharge and 30 days. Rates are per-patient.
bP values were based on the Fisher exact test.
Table V. Unadjusted and risk-adjusted odds ratios (ORs) for patients undergoing carotid endarterectomy (CEA)a
30-day death, stroke, or MI
Female vs male
Unadjusted Adjusted
OR (95% CI) Pb OR (95% CI) Pb
All CEA 1.00 (0.78-1.29) .9900 1.15 (0.89-1.48) .2958
Asymptomatic CEA 0.95 (0.66-1.36) .7685 1.05 (0.73-1.52) .7854
Symptomatic CEA 1.10 (0.78-1.56) .5884 1.24 (0.87-1.78) .2321
CI, Conﬁdence interval; MI, myocardial infarction.
aAdjusted ORs were calculated after adjusting for American Society of Anesthesiologist grade <3 vs >3, presence of coronary artery disease, aspirin use,
ejection fraction <30%, and unstable angina.
bP values were based on the Fisher exact test.
Table VI. Thirty-day outcomes for patients undergoing
carotid angioplasty and stenting (CAS)a
30-day events
CAS patients, % (No.)
Female (n ¼ 1330)Male (n ¼ 2043) Pb
Mortality 1.80 (24) 1.86 (38) >.9999
Stroke 4.44 (59) 4.99 (102) .5087
MI 1.65 (22) 1.08 (22) .1634
Death, stroke, or MI 6.69 (89) 6.80 (139) .9441
MI, Myocardial infarction.
aEvents were deﬁned as any event occurring intraoperatively, before
discharge, or between discharge and 30 days. Rates are per-patient.
bP values were based on the Fisher exact test.
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higher in symptomatic patients, with the primary end point
occurring in 5.94% women and 5.42% men. Even after risk
adjustment (Table V), no difference remained (OR, 1.15;
95% CI, 0.89-1.48; P ¼ .2958) between women and men
undergoing CEA.
CAS patients. In patients undergoing CAS (Tables VI
and VII), there again was no statistically signiﬁcant differ-
ence in outcomes in the two gender groups. The
composite death/stroke/MI rates were 6.69% in women
and 6.80% in men, higher than the 4% rate in CEA patients.
In asymptomatic patients, the event rate was higher forwomen (5.79% vs 4.55%; P ¼ .2353). There was also
a higher rate of primary end point in symptomatic men
(9.42% vs 7.84%; P ¼ .3088) than women. However,
neither of these reached statistical signiﬁcance. After risk
adjustment (Table VIII), no difference remained between
women and men (OR, 0.91; 95% CI, 0.68-1.21;
P ¼ .5115).
DISCUSSION
Revascularization has become an important treatment
option for patients with carotid artery occlusive disease.
In two landmark randomized control trials in the 1990s,
the beneﬁts of CEA over medical therapy were demon-
strated for patients with moderate or severe internal carotid
artery stenosis.3,4 Additional studies since have demon-
strated the safety and efﬁcacy of CAS as an alternative treat-
ment option.9-11 Despite these ﬁndings, the beneﬁt of
carotid revascularization in women remains unclear.
The available literature suggests that women have
a higher risk of perioperative adverse events during carotid
revascularization. In the Asymptomatic Carotid Athero-
sclerosis Study (ACAS), women had a higher rate of peri-
operative events (3.6% vs 1.7% for men) during CEA.4
Combining that with a lower rate of events for women
(8.7% vs 12.1% for men) treated with best medical therapy,
this led to a much lower 5-year risk reduction for women
(17%) compared with men (66%). Among patients with
moderate stenosis in the North American Symptomatic
Table VII. Thirty-day outcomes for symptomatic and asymptomatic patients undergoing carotid angioplasty and
stenting (CAS)a
30-day events
Asymptomatic CAS, % (No.) Symptomatic CAS, % (No.)
Female (n ¼ 743) Male (n ¼ 1098) Pb Female (n ¼ 587) Male (n ¼ 945) Pb
Mortality 1.75 (13) 1.18 (13) .3211 1.87 (11) 2.65 (25) .3882
Stroke 3.90 (29) 2.82 (31) .2287 5.11 (30) 7.51 (71) .0719
MI 1.21 (9) 1.09 (12) .8260 2.21 (13) 1.06 (10) .0841
Death, stroke, or MI 5.79 (43) 4.55 (50) .2353 7.84 (46) 9.42 (89) .3088
MI, Myocardial infarction.
aEvents were deﬁned as any event occurring intraoperatively, before discharge, or between discharge and 30 days. Rates are per-patient.
bP values were based on the Fisher exact test.
Table VIII. Unadjusted and risk-adjusted odds ratios (ORs) for patients undergoing carotid angioplasty and stenting
(CAS)a
30-day death, stroke, or MI
Female vs male
Unadjusted Adjusted
OR (95% CI) Pb OR (95% CI) Pb
All CAS 0.98 (0.75-1.29) .8994 0.91 (0.68-1.21) .5115
Asymptomatic CAS 1.29 (0.85-1.96) .2367 1.23 (0.80-1.88) .3538
Symptomatic CAS 0.82 (0.56-1.19) .2891 0.72 (0.49-1.06) .0964
CI, Conﬁdence interval; MI, myocardial infarction.
aAdjusted ORs were calculated after adjusting for American Society of Anesthesiologist grade <3 vs >3, etiology of restenosis, history of prior neck radiation,
age >80 years, and number of stents (>1).
bP values were based on the Fisher exact test.
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needed to treat with CEA to prevent one ipsilateral stroke
was 12 and the number needed to treat to prevent one
disabling stroke was 16 for men. The corresponding
numbers for women were 67 and 125, respectively, poten-
tially suggesting a lower long-term beneﬁt of surgery for
women.3 The Asymptomatic Carotid Surgery Trial
(ACST) produced similar ﬁndings, with men deriving
a higher 5-year absolute risk reduction (8.21% vs 4.08%)
than women.6
The data are somewhat unclear in the recent trials eval-
uating CAS and CEA. Women in the International Carotid
Stenting Study (ICSS) had a higher 120-day event rate for
CEA (7.6% vs 4.2%) but a lower rate for CAS (8.0% vs
8.7%).10 The opposite was found in the Carotid Revascu-
larization Endarterectomy vs Stenting Trial (CREST),
with a lower periprocedural event rate for women under-
going CEA (3.8%) than men (4.9%) but higher in CAS
(6.8% vs 4.3%).14 With potentially higher perioperative
event rates, these data raise the question of how much
women actually beneﬁt from intervention.
Gender clearly plays an important role in cardiovascular
disease. A systematic review of epidemiologic studies found
the stroke incidence rate was 33% higher and stroke preva-
lence was 41% higher in men than in women.12 When
strokes do occur, they tended to be more severe in women,with a 1-month case fatality of 24.7% compared with 19.7%
for men. However, the speciﬁc factors that lead to differen-
tial gender-speciﬁc outcomes remain unclear. Several
factors (including vessel diameter, plaque morphology,
inﬂuence of sex hormones and thromboembolic potential)
have been proposed to play an important role. However,
the overall evidence for outcome differences by gender-
speciﬁc characteristics in the published literature remains
limited.15
This study identiﬁed 9865 patients who underwent
carotid revascularization in the SVS-VR. The 30-day
outcomes in women compared with men were essentially
the same. Both gender groups had a similar 30-day
composite rate of death/stroke/MI: w4% for CEA and
7% for CAS. After stratifying by symptomatology, no differ-
ences remained in outcome. There are likely several reasons
why the results from this study differ from the published
clinical trial data. The SVS-VR was designed to capture
real-world outcomes and is available to all clinical facilities
and providers in the United States. As such, it represents
more of the routine practice found in this country as
opposed to the carefully deﬁned patient selection criteria
and practitioner credentialing that is seen in randomized
clinical trials. This difference in outcomes for actual prac-
tice compared with clinical trials has been shown in the
past for CEA and CAS.16,17
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study is that data collection in the SVS-VR began in July
2005, almost 20 years after the ﬁrst patient was enrolled
in ACAS or NASCET. During the intervening two
decades, best medical therapy improved signiﬁcantly with
the widespread availability of medications such as clopidog-
rel and statins. The use of these medications no doubt had
an effect on patient outcomes.18 Finally, we note that
women were under-represented in carotid revascularization
trials.14 It thus merits emphasis that women represented
>40% of this study cohort, more than any of the published
randomized controlled trials.
Several limitations of this analysis need to be addressed.
The inherent weaknesses in the use of a registry, such as the
SVS-VR, have previously been addressed.19 These include
the potential for treatment bias, absence of certain
anatomic information (such as plaque morphology), and
reporting bias. Perhaps the most important limitation in
this study is the lack of a comparison group for patients
treated with best medical therapy.
The hesitation in recommending carotid revasculariza-
tion to women is derived from two observations. This study
addresses the ﬁrst by focusing on the rates of perioperative
complications with carotid revascularization. However, we
were not able to determine if women had a lower event
rate if treated solely with medical therapy. Further studies
certainly are needed to determine the gender-based
outcomes in medical management of carotid artery disease.
Finally, our analysis was limited to 30-day outcomes.
As such, potential differences between genders in the
development of recurrent disease were not investigated.
Despite these limitations, data from this study still provide
valuable information about the effectiveness of carotid
revascularization in women.
CONCLUSIONS
In this large, real-world analysis, women and men
demonstrated similar rates of perioperative events after
carotid revascularization that were true for both CEA
and CAS and were independent of symptomatic status.
These data suggest that, contrary to previous reports,
women do not have a higher risk of adverse events than
men after carotid revascularization.
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nicely the historical data showing that women have always been re-
ported to have worse outcomes. So what is your hypothesis for this
change to equal outcome with men: is it better risk factor medical
management?
Dr Jeffrey Jim. I think within the past two decades there has
certainly been a difference in terms of patient selection, which we
cannot account for. I think everybody knows that medical manage-
ment has gotten signiﬁcantly better. When we compare the old
studies from 20 years ago, the best medical therapy was essentially
only aspirin and good blood pressure and glucose control. There
was no consideration of statins and, obviously, the newer-genera-
tion antiplatelet agents. So I think that patient selection is a little
bit different and medical management is very different as well.
Dr Richard Cambria (Boston, Mass). I wonder if your results
were corrected for pathology. I think you showed us that fully 25%
of the women in one of your subgroups were treated for recurrent
stenosis. And at least in the paradigm of angioplasty and stenting,
you would expect complications in that group to be signiﬁcantly
lower as a function of the fact that some of them, perhaps many,
were treated for intimal hyperplasia as opposed to degenerative pla-
que. So I wonder if the results have been corrected by throwing
out the restenosis patients?
Dr Jim. We did not throw them out per se but accounted for
disease etiology in our analysis. We did not have additional data
points, such as plaque characteristics, included in the data, but
we certainly accounted for the etiology of the disease.
Dr Cambria. Is it true that 25% of the women were treated
for recurrent stenosis, or was that only in the carotid angioplasty
and stenting (CAS) group?
Dr Jim. That was only the stenting group. There was only 1%
to 2% of the endarterectomy group that was treated for restenosis.
Dr Cambria. Well, I still think that with that percentage of
patients in theCAS that has to be corrected for in terms of comparing
complications, but appreciate your presentation of a lot of data.Dr David Rigberg (Los Angeles, Calif). You did mention the
selection bias. And I was wondering, from your data set, is there
any way to know what the percentage of men vs women under-
going any intervention was, so what the number was, so that
maybe what we are seeing is just fewer women undergoing a proce-
dure based on the type and level of disease they have?
Dr Jim. The way the registry works is every patient in each
individual center should be included. In our total study we had
about 10,000 patients, with about 40% being women. And if
you look at the different subgroups in terms of the stenting as
well as the endarterectomy, they were about the same; it was about
a 60/40 split.
Dr John Ricotta (Washington, D.C.). This is not the same
as a comparison, like as in ACAS (Asymptomatic Carotid Athero-
sclerosis Study) or the ACST (Asymptomatic Carotid Surgery
Trial) where you were looking at medical management vs surgical
management. So it is conceivable that these results, while they
don’t show a difference in surgical outcome, still do not prove
the hypothesis that for asymptomatic patients there is as much
beneﬁt for men as women. Can you comment on that?
Dr Jim. I think the hesitation to treating women comes from
two factors. One is the fact that there was a higher rate of perioper-
ative events, and the second one was that women tend to just have
fewer events on medical therapy. Our study essentially is able to
only address the ﬁrst part. We were able to compare men and
women essentially showing that they have equivalent surgical
outcomes. But we did not have data on treatment with optimal
medical therapy alone. And you are right, potentially, that is the
group that has the best results and certainly do not need
intervention.
Dr Ricotta. Did you have any data on the prevalence of the
use of patching in these patients, or was that not available?
Dr Jim. That is not available because some centers were
doing eversion endarterectomies so it is hard to separate those
patients out.
